A phase III trial to study Esophageal Adenocarcinoma
This study is being done to compare the effects, good and/or bad, of the addition of trastuzumab to standard chemotherapy, radiation, and surgery for patients with HER2 positive esophageal cancer.
This research study is led by Dr. Seth Kaufman.
Contact: Dawn DeMarinis, 413-794-4362
Cancer - Esophogus,
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
Participants must have confirmed esophageal cancer, HER2 positive, and no prior chemotherapy or radiation.
Interventional (Clinical Trial), Randomized